Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: " Medroxyprogesterone improves nocturnal breathing in postmenopausal women with chronic obstructive pulmonary disease. | Respiratory Research BioMed Central Research Open Access Medroxyprogesterone improves nocturnal breathing in postmenopausal women with chronic obstructive pulmonary disease Tarja Saaresranta 1 2 Tero Aittokallio3 Karri Utriainen1 and Olli Polo1 2 4 Address 1Sleep Research Unit at the Department of Physiology University of Turku Sleep Research Unit Dentalia Lemminkaisenkatu 2 20520 Turku Finland 2Department of Pulmonary Diseases Turku University Central Hospital 20520 Turku Finland 3Department of Mathematics University of Turku 20014 Turku Finland and 4Department of Pulmonary Diseases Tampere University Central Hospital 2000 33521 Tampere Finland Email Tarja Saaresranta - Tero Aittokallio - Karri Utriainen - utriainen@ Olli Polo - ollipolo@ Corresponding author Published 04 April 2005 Received 17 January 2005 Respiratory Research 2005 6 28 doi 1465-9921 -6-28 Accepted 04 April 2005 This article is available from http content 6 1 28 2005 Saaresranta et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Progestins as respiratory stimulants in chronic obstructive pulmonary disease COPD have been investigated in males and during wakefulness. However sleep and gender may influence therapeutic responses. We investigated the effects of a 2-week medroxyprogesterone acetate MPA therapy on sleep and nocturnal breathing in postmenopausal women. Methods A single-blind placebo-controlled trial was performed in 15 postmenopausal women with moderate to severe COPD. A 12-week trial included 2-week treatment periods with placebo and MPA 60 mg d 14 days . All patients underwent a polysomnography with monitoring .
